PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $540 | -37.1% | 16 | -42.9% | 0.00% | – |
Q3 2023 | $859 | -53.4% | 28 | -39.1% | 0.00% | -100.0% |
Q2 2023 | $1,843 | +63.8% | 46 | +64.3% | 0.00% | – |
Q1 2023 | $1,125 | +4.1% | 28 | 0.0% | 0.00% | – |
Q4 2022 | $1,081 | -73.0% | 28 | -66.7% | 0.00% | -100.0% |
Q3 2022 | $4,000 | – | 84 | +1300.0% | 0.00% | – |
Q2 2022 | $0 | -100.0% | 6 | -85.4% | 0.00% | -100.0% |
Q1 2022 | $3,000 | – | 41 | +583.3% | 0.00% | – |
Q4 2021 | $0 | – | 6 | 0.0% | 0.00% | – |
Q3 2021 | $0 | – | 6 | 0.0% | 0.00% | – |
Q2 2021 | $0 | -100.0% | 6 | -95.0% | 0.00% | -100.0% |
Q1 2021 | $8,000 | -11.1% | 119 | -21.7% | 0.00% | -25.0% |
Q4 2020 | $9,000 | 0.0% | 152 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $9,000 | +28.6% | 152 | 0.0% | 0.00% | +33.3% |
Q2 2020 | $7,000 | +250.0% | 152 | +123.5% | 0.00% | +200.0% |
Q1 2020 | $2,000 | -71.4% | 68 | -59.3% | 0.00% | -75.0% |
Q4 2019 | $7,000 | – | 167 | +2285.7% | 0.00% | – |
Q2 2017 | $0 | – | 7 | 0.0% | 0.00% | – |
Q1 2017 | $0 | – | 7 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |